Zacks Investment Research upgraded shares of Tyme Technologies (NASDAQ:TYME) from a sell rating to a hold rating in a research note published on Wednesday morning, Zacks.com reports.
According to Zacks, “Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body’s immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. “
Separately, HC Wainwright reissued a buy rating and issued a $9.50 price objective on shares of Tyme Technologies in a research report on Thursday, February 6th.
Shares of TYME opened at $1.15 on Wednesday. The firm has a market capitalization of $143.72 million, a PE ratio of -4.79 and a beta of 0.54. The company’s 50-day moving average is $1.41 and its 200-day moving average is $1.32. Tyme Technologies has a fifty-two week low of $0.92 and a fifty-two week high of $2.40.
Tyme Technologies (NASDAQ:TYME) last issued its quarterly earnings data on Wednesday, February 5th. The company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. As a group, sell-side analysts expect that Tyme Technologies will post -0.22 EPS for the current year.
In other news, major shareholder Michael Demurjian sold 20,000 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.64, for a total value of $32,800.00. Following the transaction, the insider now directly owns 25,050,521 shares of the company’s stock, valued at $41,082,854.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 180,000 shares of company stock worth $240,800 over the last three months. Insiders own 27.17% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in TYME. Morgan Stanley grew its stake in shares of Tyme Technologies by 187.8% in the second quarter. Morgan Stanley now owns 139,579 shares of the company’s stock valued at $170,000 after acquiring an additional 91,081 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Tyme Technologies during the third quarter worth about $71,000. UBS Group AG grew its stake in Tyme Technologies by 49.1% during the fourth quarter. UBS Group AG now owns 90,630 shares of the company’s stock worth $127,000 after buying an additional 29,829 shares in the last quarter. Barclays PLC grew its stake in Tyme Technologies by 102.1% during the fourth quarter. Barclays PLC now owns 59,040 shares of the company’s stock worth $83,000 after buying an additional 29,821 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. grew its stake in Tyme Technologies by 12,625.0% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 25,450 shares of the company’s stock worth $36,000 after buying an additional 25,250 shares in the last quarter. Institutional investors and hedge funds own 11.76% of the company’s stock.
About Tyme Technologies
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Read More: How Do You Calculate Return on Equity (ROE)?
Get a free copy of the Zacks research report on Tyme Technologies (TYME)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tyme Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tyme Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
